JRKL and breast carcinoma: In particular, we identified several gained and lost enhancer-promoter interactions (EPIs) and their corresponding DEGs such as FA2H, FOXA1, JRKL and EZH2, many of which were involved in chromatin organization, Notch and breast cancer signaling pathways and have been known to be closely related to drug resistance or epigenetic regulation in human cancer (Herrero et al., 2008; Roe et al., 2017; Toh et al., 2017; Nussinov et al., 2021).